Efficacy of erythropoiesis-stimulating agents and their effect on quality of life in anemic patients with lymphoproliferative diseases
- Authors: Romanenko NA1, Bessmeltsev SS1, Karmatskaya II1, Potikhonova NA1, Abdulkadyrov KM1
-
Affiliations:
- Russian Scientific and Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russia
- Issue: Vol 94, No 4 (2013)
- Pages: 468-473
- Section: Theoretical and clinical medicine
- URL: https://journals.rcsi.science/kazanmedj/article/view/1951
- DOI: https://doi.org/10.17816/KMJ1951
- ID: 1951
Cite item
Full Text
Abstract
Aim. To study the effect of different erythropoiesis-stimulating agents and to assess their influence on quality of life in anemic patients with lymphoproliferative diseases. Methods. The study included 137 patients with lymphoproliferative diseases (Burkitt’s lymphoma, B-cell chronic lymphocytic leukemia, multiple myeloma) and anemia, who were distributed to 2 groups. The first group consisted of 90 patients who received chemotherapy and erythropoiesis-stimulating agents [epoetinum alpha 40 000 IU once a week (n=41) or epoetinum beta 30 000 IU once a week (n=27) or darbaepoetinum alpha 500 μg once every third week (n=22)]. The treatment duration varied from 4 to 20 weeks (mean 9.3±4.1 weeks). The second (control) group included 47 patients with comparable baseline clinical and hematological characteristics receiving only chemotherapy. Patients were estimated as treatment responders if there was an increase of hemoglobin level by 20 g/L or hemoglobin level reached at least 110 g/L. All patients were administered FACT-An (Functional Assessment of Cancer Therapy, Anemia scale) questionnaire to assess quality of life. Results. In patients receiving erythropoiesis-stimulating agents the positive treatment response was more frequent compared to the control group (68.9 и 29.8% correspondingly). The number of patients requiring erythrocytes transfusion decreased from 29 to 10 (34.5%) in the first group and from 14 to 8 (57.1%) in the control group. There was no significant differences found in comparing different erythropoiesis-stimulating agents. The positive response was observed in 68.3% of patients treated with epoetinum alpha, 70.1% - epoetinum beta, 68.2% - darbaepoetinum alpha. The significant increase in quality of life measured by FACT-An was observed in erythropoiesis-stimulating agents responders. Conclusion. The administration of erythropoiesis-stimulating agents in patients with lymphoproliferative diseases and anemia is an effective way of controlling anemia, significantly reducing the need for erythrocytes transfusion and improving quality of life.
Full Text
##article.viewOnOriginalSite##About the authors
N A Romanenko
Russian Scientific and Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russia
Email: rom-nik@yandex.ru
S S Bessmeltsev
Russian Scientific and Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russia
I I Karmatskaya
Russian Scientific and Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russia
N A Potikhonova
Russian Scientific and Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russia
K M Abdulkadyrov
Russian Scientific and Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russia
References
- Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. - СПб.: Диалект, 2004. - 448 с.
- Бессмельцев С.С., Гусева С.А. Современные принципы лечения анемии у пациентов с онкогематологическими заболеваниями // Укр. ж. гематол. та трансфузiол. - 2009. - №1. - С. 5-17.
- Романенко Н.А. Патогенез и терапия анемии препаратами рекомбинантного эритропоэтина у онкогематологических больных // Онкогематология. - 2012. - №3. - С. 20-29.
- Campos M.P.O., Hassan B.J., Riechelmann R., Del Giglio A. Cancer-related fatigue: a practical review // Ann. Oncol. - 2011. - Vol. 22, N 6. - P. 1273-1279.
- Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue // Semin. Hematol. - 1997. - Vol. 34. - P. 13-19.
- Christodoulou C., Dafni U., Aravantinos G. et al. Effects of epoetin-α on quality of life of cancer patients with solid tumors receiving chemotherapy // Anticanc. Res. - 2009. - Vol. 29. - P. 693-702.
- Lind M., Vernon C., Cruickshank D. et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life // Br. J. Cancer. - 2002. - Vol. 86. - P. 1243-1249.
- Ludwig H., Van Belle S., Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients // Eur. J. Cancer. - 2004. - Vol. 40. - P. 2293-2306.
- Moullet I., Salles G., Ketterer N. et al. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients // Ann. Oncol. - 1998. - Vol. 9. - P. 1109-1115.
- Rizzo J.D., Brouwers M., Hurley P. et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer // Blood. - 2010. - Vol. 116, N 20. - P. 4045-4059.
- Romanenko N.A. Study of efficacy red blood cell transfusions and their influencing on quality of life in hematological malignancies patients with anemia // Haematologica. - 2012. - Vol. 97, suppl. 1. - P. 163.
- Steurer M., Wagner H., Gastel G. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey // Wien. Klin. Wochenschr. - 2004. - Vol. 116, N 11-12. - P. 367-372.
- Vadhan-Raj S., Zhou X., Sizer K. et al. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC // The Oncologist. - 2010. - Vol. 15. - P. 1359-1369.
- Yellen S.B., Cella D.F., Webster K. et al. Measuring fatigue, and other anemia related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system // J. Pain Symptom Manage. - 1997. - Vol. 13. - P. 63-74.
- Yoshimura A., Kobayashi K., Fumimoto H. et al. Cross-cultural validation of japanese Functional Assessment of Cancer-Therapy Anemia (FACT-An) // J. Nippon. Med. Sch. - 2004. - Vol. 71, N 5. - P. 314-322.
